



Jenny C. Chang, MD

Emily Hermann Chair in Cancer Research
Houston Methodist Research Institute Director, Houston Methodist
Cancer Center
Houston, TX

Jenny C. Chang is Director of the Cancer Center at Houston Methodist Hospital in Houston, Texas, and Professor at Weill Cornell Medical School. She obtained her medical degree at Cambridge University in England, and then completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research in the United Kingdom. She was also awarded a research doctorate from the University of London. Her recent work has focused on the intrinsic therapy resistance of cancer stem cells (CSCs), which has led to several publications and international presentations. In addition, she has been awarded several federal grants to evaluate novel biologic agents, and holds patents on new technologic advances and therapeutic agents.

Chang has worked in the field of cancer stem cells for more than ten years. After her discovery that CSCs are chemo-resistant, and that targeting the EGFR/HER2 pathway can decrease this subpopulation, Chang has played a key role in demonstrating some of the limitations and mechanisms of CSCs (Creighton et al., 2009; Li et al., 2008). Her work is now focused on the mechanisms that regulate CSCs, as well as initiating and planning clinical trials that target this critical tumor initiating subpopulation. She is also interested in characterizing the cross-talk between these different pathways that may lead to mechanisms of resistance, and has identified some of the chief regulatory pathways, including inducible nitric oxide (iNOS) and JAK/STAT3 signaling involved in CSC self-renewal (Dave et al., 2014; Dave et al., 2017). She is a world-renown clinical investigator, credited as one of the first to describe intrinsic chemo-resistance of CSCs.